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Abstract
Background: Specific antibodies mediate humoral and cellular protection against invading pathogens such as Streptococcus
pneumoniae by activating complement mediated immunity, promoting phagocytosis and stimulating bacterial clearance.
The emergence of pneumococcal strains with high levels of antibiotic resistance is of great concern worldwide and a serious
threat for public health.
Methodology/Principal Findings: Flow cytometry was used to determine whether complement-mediated immunity
against three antibiotic-resistant S. pneumoniae clinical isolates is enhanced in the presence of sub-inhibitory concentrations
of cefditoren and ceftriaxone. The binding of acute phase proteins such as C-reactive protein and serum amyloid P
component, and of complement component C1q, to pneumococci was enhanced in the presence of serum plus either of
these antibiotics. Both antibiotics therefore trigger the activation of the classical complement pathway against S.
pneumoniae. C3b deposition was also increased in the presence of specific anti-pneumococcal antibodies and sub-inhibitory
concentrations of cefditoren and ceftriaxone confirming that the presence of these antibiotics enhances complement-
mediated immunity to S. pneumoniae.
Conclusions/Significance: Using cefditoren and ceftriaxone to promote the binding of acute phase proteins and C1q to
pneumococci, and to increase C3b deposition, when anti-pneumococcal antibodies are present, might help reduce the
impact of antibiotic resistance in S. pneumoniae infections.
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Introduction
Streptococcus pneumoniae, the pneumococcus, is the leading
bacterial cause of community-acquired pneumonia, bacteremia
and meningitis, especially among young children and older adults
[1]. Invasive pneumococcal disease (IPD) is associated with high
morbidity and mortality, and may be fatal despite appropriate
antibiotic treatment. The emergence of strains for which the
minimum inhibitory concentrations (MICs) are high, complicates
the success of the antibiotic treatment and poses a serious threat
worldwide [2]. Immunization is a safe an highly efficient approach
to preventing IPD [3]. Induction of complement immunity leads
to the formation of the key component C3b that plays a major role
in innate and adaptive immunity [4,5]. Activation of the classical
pathway is essential in the host immune response to S. pneumoniae;
indeed, it is the most important route for complement activation
against this pathogen in mice and humans [6,7]. The classical
pathway can also be activated by natural IgM, acute phase
proteins such as C-reactive protein (CRP) and serum amyloid P
component (SAP) or by the lectin SIGN-R1 [7,8,9,10].
b-lactam antibiotics have little effect on the chemotaxis of
neutrophils towards areas of infection. However, some can
increase the oxidative burst of neutrophils by scavenging oxidative
species or the inhibition of myeloperoxidase [11]. Enhancing this
oxidative burst response by b-lactams may render some bacterial
species more susceptible to phagocytic killing, although the
mechanism is not fully understood [11,12]. In this sense, we have
previously reported that the combined effects of amoxicillin or
cefotaxime with specific antibodies increases the rate of bacterial
clearance in a mouse model [13]. In addition, the presence of anti-
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pneumococcal antibodies led to therapeutic efficacy with sub-
inhibitory concentrations of b-lactam antibiotics [14]. Moreover,
phagocytosis mediated by human and mouse neutrophils was
increased when antibiotic-resistant pneumococcal strains were
incubated with serum containing specific antibodies and sub-MIC
concentrations of b-lactams [15]. Whether the synergism between
anti-pneumococcal antibodies and b-lactam antibiotics is due to a
direct interaction of the antimicrobial drug with the host immune
system is unknown.
In the present work, three antibiotic-resistant pneumococcal
strains were used to investigate the stimulation of complement-
mediated immunity by sub-inhibitory concentrations of cefditoren
(CDN) and ceftriaxone (CRO) in the presence of specific
antibodies and serum components.
Materials and Methods
Ethics Statement
Healthy subjects gave their written informed consent prior to
the collection of their serum. This sampling was approved by the
Centro de Investigaciones Biolo´gicas (CIB) Research Ethics
Committee (Approval Reference: CIB-FJD 06010017). The
immunization of animals was performed at Instituto de Salud
Carlos III (ISCIII) in accordance with Spanish legislation (RD
1201/2005) and EU regulations (86/609/EEC). The animal
experiments performed in this work were approved by the Animal
Care and Use Committee of ISCIII (CBA PA 52_2011-v2).
Bacterial strains and growth conditions
S. pneumoniae clinical isolates used in this study included strain
1515/97 [serotype 6B; penicillin (PEN) MIC = 2 mg ml21; CDN
MIC = 1 mg ml21; CRO MIC = 2 mg ml21], strain 69 (serotype
19F; PEN MIC = 2 mg ml21 ml; CDN MIC = 2 mg ml21; CRO
MIC = 4 mg ml21) and strain 48 (serotype 23F; PEN
MIC = 16 mg ml21; CDN MIC = 4 mg ml21; CRO MIC =
8 mg ml21). Pneumococcal isolates were cultured at 37uC in 5%
CO2 on blood agar plates or in Todd-Hewitt broth supplemented
with 0.5% yeast extract to an optical density at 580 nm (OD580) of
0.4 (approximately 108 CFU ml21) and stored at 270uC in 10%
glycerol as single-use aliquots.
Antibiotics and susceptibility studies
CDN was supplied from Tedec-Meiji Farma S. A. (Madrid,
Spain) and CRO was purchased from Sigma-Aldrich Chemical
Co. (St Louis, MO). Susceptibility was determined (in triplicate) by
the agar dilution technique [16] in accordance with the criteria of
the Clinical and Laboratory Standards Institute (CLSI).
Human and mouse sera
Serum samples from five healthy male volunteers unvaccinated
against S. pneumoniae (median age of 40 years), were obtained
according to institutional guidelines and stored as single-use
aliquots at 270uC to use as a source of C1q and CRP.
Hyperimmune serum (HS) from mice was obtained as previously
described [14,15]. IgG levels in HS against strains 1515/97, 69
and 48 were 1056 mg ml21, 371 mg ml21 and 251 mg ml21
respectively [15].
Complement factors binding to S. pneumoniae strains
The deposition/binding of C3b, C1q and the acute phase
proteins CRP and SAP to bacterial cells was assessed by flow
cytometry as described previously [7,8]. Briefly, C3b deposition
was analyzed by incubating 56106 CFU of S. pneumoniae in 10 ml
of mouse serum (diluted to 50% in PBS) for 2 h supplemented or
not with 0.5 MIC and 0.25 MIC of either CDN or CRO. The
bacteria were then incubated for 30 min on ice with fluorescein
isothiocyanate (FITC)-conjugated polyclonal goat anti-mouse C3b
antibody (ICN-Cappel) diluted 1/300 in PBS. Bacteria were then
fixed in 3% paraformaldehyde and analyzed on a FACS Calibur
flow cytometer (BD Biosciences) using forward and side scatter
parameters to gate on at least 25,000 cells. The results were
expressed as a relative % fluorescence index, providing a measure
of the proportion of fluorescent bacteria positive for C3b, and the
intensity of fluorescence, which quantifies bound C3b [6,17].
Naive mouse serum, HS and HS treated with MgCl2 (2 mM)-
EGTA (2 mM) to inhibit the activity of the lectin and classical
pathways (thus allowing only alternative pathway activation), were
used in C3b deposition assays [18,19]. The interaction of C1q,
CRP and SAP with S. pneumoniae strains in the presence or absence
of both b-lactam antibiotics was evaluated following a flow
cytometry method similar to that used in the C3b deposition assay.
Pneumococcal strains (56106 CFU) were incubated with 10 ml of
human or mouse serum (diluted to 50% in PBS) for 1 h with or
without 0.5 MIC and 0.25 MIC of each antibiotic. CRP and SAP
binding to the pneumococcal surface was assessed using a
polyclonal rabbit anti-human CRP antibody (Calbiochem) or a
polyclonal rabbit anti-mouse SAP antibody (GenScript) and a
FITC-conjugated goat anti-rabbit IgG secondary antibody (Ser-
otec), both diluted 1/300 in PBS [8]. C1q deposition was analyzed
using a FITC-conjugated polyclonal sheep anti-human C1q
antibody (Serotec) and a polyclonal rabbit anti-mouse C1q
antibody (Abcam), followed by a secondary FITC-conjugated
polyclonal goat anti rabbit (Serotec), both at a dilution of 1/300
[8].
Statistical analysis
The data presented are the means and standard deviations for
three independent experiments with at least three replicas. The
results of CRP, SAP, C1q and C3b deposition assays in the
presence of serum and exogenous sub-inhibitory concentrations of
CDN and CRO were compared to results for control sera in the
absence of each antibiotic by using the two-tailed Student’s t test
(for two groups). Analysis of variance (ANOVA) plus a post hoc
Dunnett test was used for multiple comparisons. GraphPad InStat
version 3.0 (GraphPad Software, San Diego, CA) was used for
statistical analysis.
Results
Interaction of acute phase proteins with antibiotic-
resistant pneumococcal strains in the presence of CDN or
CRO
The recognition of the different S. pneumoniae strains by human
CRP and mouse SAP was investigated by flow cytometry in the
presence or absence of sub-inhibitory concentrations of CDN or
CRO. For all the strains, and with both antibiotics, the binding of
human CRP and mouse SAP was significantly increased (Fig. 1).
These results suggest that recognition of antibiotic-resistant S.
pneumoniae strains by acute phase proteins such as CRP and SAP is
enhanced when bacteria are exposed to these antibiotics.
Activation of the classical complement pathway against
antibiotic-resistant S. pneumoniae strains by CDN and
CRO
To investigate the activation of the classical pathway in the
presence of the antibiotics, pneumococcal resistant strains were
incubated with human or mouse serum in the presence or absence
b-Lactams Enhance Immunity to S. pneumoniae
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of sub-inhibitory concentrations of CDN or CRO, and the
deposition of either human or mouse C1q was analyzed. Bacteria
incubated with human or mouse sera supplemented with 0.5 MIC
and 0.25 MIC of either CDN or CRO showed greater levels of
C1q bound to the bacterial surface than those incubated in serum
alone (Fig. 2). These results confirm that the capacity of C1q to
recognize S. pneumoniae and further stimulate the classical
complement pathway is enhanced in the presence of these
antibiotics (Fig. 2).
C3b deposition mediated by serum containing anti-
pneumococcal antibodies and sub-inhibitory
concentrations of CDN or CRO
Pneumococcal isolates were incubated in sera from immunized
mice in the presence or absence of sub-inhibitory concentrations of
CDN and CRO or in PBS and serum heated to 65uC for 30 min
(heat inactivated serum; HIS) as negative controls (Fig. 3). HIS
conserves antibody function but lacks any complement activity,
demonstrating the specificity of the assay for detecting functional
C3b. No C3b deposition was detected on pneumococcal strains
incubated in PBS or HIS, (Fig. 3). Opsonization of the different
strains with the corresponding HS and 0.5 MIC or 0.25 MIC of
either CDN or CRO significantly increased C3b deposition
compared to that seen on bacteria incubated in serum alone
(Fig. 3). Strain 1515/97 showed the strongest C3b deposition in
the presence of the antibiotics (Figs. 3E and F). Overall, this C3b
deposition was improved when bacteria were opsonized with
serum containing anti-pneumococcal antibodies in the presence of
sub-inhibitory concentrations of CDN or CRO, although depo-
sition was significantly greater in the presence of CDN (P,0.05,
two-tailed t test) for the serotype 6B strain (Figs. 3E and F).
To demonstrate the importance of antibodies in the increased
C3b deposition mediated by CDN or CRO, bacteria were
incubated using non-immune mouse serum (NIS) and the results
were compared with those obtained with HS. The results
confirmed the antibodies to be necessary for the antibiotic-
Figure 1. Binding of acute phase proteins to the different bacterial strains in the presence or absence of CDN or CRO. Deposition of
human CRP (white bars) and mouse SAP (grey bars) in the presence of serum alone (dotted bars) or serum with 0.5 MIC (open bars) and 0.25 MIC
(hatched bars) of either cefditoren (CDN) or ceftriaxone (CRO). (A) Deposition of CRP and SAP on the surface of the serotype 23F strain. (B) Deposition
of CRP and SAP on the surface of the serotype 19F strain. (C) Deposition of CRP and SAP on the surface of the serotype 6B strain. (D) Example of a
flow cytometry histogram for CRP binding on the serotype 23F strain. (E) Example of a flow cytometry histogram for SAP binding on the 6B strain.
Results are expressed as relative % fluorescence indices relative to the results for sera in the absence of antibiotics. Error bars represent standard
deviations; asterisks mark statistically significant differences with sera in the absence of antibiotics (two-tailed Student t test *P,0.05, **P,0.01,
***P,0.001). ***P,0.001 for serotypes 23F and 6B and * P,0.05 for serotype 19F in the multiple comparison of CRP binding (one-way ANOVA with a
post hoc Dunnet test). * P,0.05 for serotypes 23F and 19F and ** P,0.01 for serotype 6B in the multiple comparison of SAP binding (one-way
ANOVA with a post hoc Dunnet test).
doi:10.1371/journal.pone.0044135.g001
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enhanced C3b deposition (Fig. 4). Activation of the alternative
complement pathway by the antibiotics was also investigated. HS
was treated with a mixture of magnesium-EGTA to chelate the
calcium ions needed for classical and lectin pathway activation; the
only functional cascade left was, therefore, the alternative
pathway. Loss of classical pathway activity prevented any
enhancement of C3b deposition in the presence of the antibiotics.
This confirms that the increased recognition of S. pneumoniae by the
complement system in the presence of sub-inhibitory concentra-
tions of CDN or CRO is mediated by the activation of the classical
pathway (Fig. 4).
Discussion
IPD occurs when colonizing microorganisms in the nasophar-
ynx translocate to alveolar spaces and bloodstream, causing
bacteraemic pneumonia and sepsis, or when they traverse the
blood-brain barrier, causing meningitis [20]. In the absence of
antibiotic treatment, the clinical outcome depends entirely on the
interactions between bacterial virulence factors and the host
defense mechanisms. Clearance of pneumococci from the systemic
circulation strongly depends on opsonization by complement
components and phagocytosis [21,22]. PEN-resistant S. pneumoniae
strains have a peptidoglycan structure containing more hydro-
phobic peptides (carrying dialanyl or alanylserine cross bridges)
than PEN-susceptible isolates [23]. Muramyl dipeptide, the
breakdown product of bacterial cell walls from PEN-treated
pneumococci, is a powerful stimulator of the immune response.
The impaired released of this cell wall component in resistant
strains might be involved in the reduced immunogenicity of
capsular serotypes usually associated with PEN-resistance [24,25].
In this sense, HS against the serotype 6B strain (that had the lowest
MIC to CDN and CRO among the three strains used) contained
Figure 2. C1q deposition in the presence or absence of CDN or CRO. Deposition of human C1q (white bars) or mouse C1q (grey bars) using
serum alone (dotted bars) or serum with 0.5 MIC (open bars) and 0.25 MIC (hatched bars) of either CDN or CRO. (A) Deposition of C1q on the surface
of the serotype 23F strain. (B) Deposition of C1q on the surface of the serotype 19F strain. (C) Deposition of C1q on the surface of the serotype 6B
strain. (D) Example of a flow cytometry histogram for human C1q binding on the 23F strain. (E) Example of a flow cytometry histogram for mouse C1q
on the 19F strain. Results are expressed as relative % fluorescence indices relative to the results for sera in the absence of antibiotics. Error bars
represent standard deviations; asterisks mark results that are statistically significant compared to those for sera with no antibiotics (two-tailed Student
t test *P,0.05, **P,0.01, ***P,0.001). ***P,0.001 for strains of serotypes 23F and 19F and * P,0.05 for 6B strain in the multiple comparison of
human C1q binding (one-way ANOVA with a post hoc Dunnet test). **P,0.001 for serotypes 23F and 6B and * P,0.05 for serotype 19F in the
multiple comparison of mouse C1q binding (one-way ANOVA with a post hoc Dunnet test).
doi:10.1371/journal.pone.0044135.g002
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Figure 3. C3b deposition on the surface of the different bacterial strains using hyperimmune serum containing anti-pneumococcal
antibodies in the presence or absence of 0.5 MIC and 0.25 MIC of CDN or CRO. (A) Deposition of C3b on the surface of the serotype 23F
strain. (B) Example of a flow cytometry histogram for C3b deposition on the serotype 23F strain. (C) Deposition of C3b on the serotype 19F strain. (D)
Example of a flow cytometry histogram for C3b binding on the serotype 19F strain. (E) Deposition of C3b on the surface of the serotype 6B strain. (F)
Example of a flow cytometry histogram for C3b binding on the serotype 6B strain. Results are expressed as relative % fluorescence indices relative to
the results for sera in the absence of antibiotics. Error bars represent standard deviations; asterisks mark results that are statistically significant
b-Lactams Enhance Immunity to S. pneumoniae
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the higher antibody titer compared to HS against the 19F and 23F
strains [15].
It is widely accepted that b-lactam antibiotics exert their
bactericidal activity by a direct effect of the antimicrobial agent on
the target microorganism. However, IPD is associated to high
compared to those for sera in the absence of antibiotics (two-tailed Student t test *P,0.05, **P,0.01, ***P,0.001). ***P,0.001 for all the strains in
the multiple comparison of C3b binding (one-way ANOVA with a post hoc Dunnet test).
doi:10.1371/journal.pone.0044135.g003
Figure 4. C3b deposition on the different bacterial strains using non-immune mouse serum (NIS), hyperimmune mouse serum (HS)
and HS treated with EGTA (HS-EGTA). Deposition of C3b was measured using NIS (white bars), HS (light grey bars) or HS-EGTA (dark grey bars) in
the absence or presence of 0.5 MIC CFD or CRO. (A) Deposition of C3b on the surface of the serotype 23F strain. (B) Deposition of C3b on the surface
of the serotype 19F strain. (C) Deposition of C3b on the surface of the serotype 6B strain. (D) Example of a flow cytometry histogram for C3b binding
on the serotype 6B strain incubated with NIS. (E) Example of a flow cytometry histogram for C3b binding on the serotype 6B strain incubated with HS-
EGTA. Results are expressed as relative % fluorescence indices relative to the results for sera in the absence of antibiotics. Error bars represent
standard deviations; asterisks mark results that are statistically significant compared to those for sera in the absence of antibiotics (two-tailed Student
t test, ***P,0.001).
doi:10.1371/journal.pone.0044135.g004
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rates of morbidity and mortality worldwide despite proper
antibiotic therapy [24]. This common lack of antibiotic efficacy
is especially evident in immunocompromised patients, suggesting
that the recovery of these patients depends on the successful joint
action of antibiotics and host defense mechanisms. The emergence
of pneumococcal strains strongly resistant to antibiotics could
therefore jeopardize the success of the antibiotic therapy [2].
Alteration of cell surface structures by antibiotics might result in
greater exposure of deeper antigenic epitopes that are normally
hidden or hardly exposed. Such exposure may promote opson-
ization by several host defense components such as acute phase
proteins, enhancing the recognition of the microbial pathogen by
professional phagocytes. In this sense, the use of cephalosporins
has been linked to an increased bactericidal serum activity against
Escherichia coli and Pseudomonas aeruginosa [26,27]. Alternatively,
antibiotics might reduce the expression of virulence factors
involved in inhibition of complement activation. Indeed, a recent
report has confirmed that certain antibiotics at sub-inhibitory
concentrations modify virulence gene expression in S. aureus [28].
CRP and SAP belong to the pentraxin family and are the main
acute phase proteins in humans and mice, respectively
[8,29,30,31]. CRP levels rise dramatically during pneumococcal
infection highlighting the importance of this acute phase protein as
a sentinel molecule against this pathogen [30]. One of the main
roles played by CRP and SAP in host defense against pneumo-
cocci is the opsonization of the microorganism and induction of
phagocytosis via Fcc-receptors [8,32,33]. The present results show
that the recognition of S. pneumoniae by CRP and SAP was
enhanced when bacteria were opsonized with serum in the
presence of sub-inhibitory concentrations of CDN or CRO
suggesting that these antibiotics allow CRP and SAP to recognize
S. pneumoniae more efficiently. This agrees with the findings of a
recent study in which we detected increased phagocytosis (both by
human and mouse neutrophils) of S. pneumoniae when opsonized
with serum containing specific anti-pneumococcal antibodies and
sub-inhibitory concentrations of either CDN or CRO [15].
Pentraxin 3 has also been shown to be very effective in
combination to antimycotic drugs against Aspergillus fumigatus
infections, stimulating the antifungal activity of effector phagocytes
[34]. Increased damage of the microbial surface by antimicrobial
drugs might allow certain bacterial components of the cell
envelope to become more accessible to complement components
and antibodies. Exposure of Klebsiella pneumoniae strains to serum
complement and b-lactam antibiotics increased C3 levels on the
bacterial surface [35].
In complement-mediated defense against S. pneumoniae, the
classical pathway is triggered by the first component (C1q) which
directly recognizes certain ligands on the microbial surface or can
be activated by acute phase proteins and specific immunoglobulins
[7,36]. The present results showed that C1q deposition on the
bacterial surface was increased in the presence of the studied
antibiotics, confirming that bacterial alterations caused by CDN
and CRO enhance complement-mediated immunity to S.
pneumoniae via a mechanism dependent on classical pathway
activation.
Once the complement cascade is activated, the central
complement component C3b is formed by a complex enzymatic
system [4,5]. C3b deposition on the bacterial surface was
significantly increased when bacteria were opsonized with serum
and sub-MIC levels of CDN or CRO. Certainly, anti-pneumo-
coccal antibodies can modify the bacteraemic profile and delay the
course of IPD in mice models [37,38], and indeed, the present
results obtained when using NIS show that specific antibodies are
important for the enhanced C3b deposition. A previous study
involving the same strains showed that bacterial clearance and
survival rates mediated by anti-pneumococcal antibodies were
greatly improved after the administration of a sub-therapeutic dose
of either CDN or CRO [15]. These findings mirror the results of
the present complement immunity assays, and demonstrate that
the collaboration of complement-mediated immunity (via the
classical pathway) and b-lactam therapy for IPD favours phago-
cytosis.
Early antibiotic treatment is essential to prevent severe
morbidity and mortality because delays in treatment increase the
chances of disability and death. This problem becomes worse
when the invading pathogen harbors resistance to antibiotics.
When faced with highly resistant pneumococcal strains, treatment
with CFD or CRO may be a novel strategy to reduce the risk of
treatment failure in people previously vaccinated against S.
pneumoniae by enhancing the efficiency of the complement-
mediated immune response.
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